Data monitoring experience in the AIDS toxoplasmic encephalitis study

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The toxoplasmic encephalitis (TOXO) study was designed to determine whether primary prophylaxis with pyrimethamine (25 mg thrice weekly) or clinidamycin (300 mg twice daily) would reduce the incidence of toxoplasmic encephalitis (TE) among HIV-infected patients considered at risk for the opportunistic infection. Using a modified double-blind design, patients were randomized to clindamycin or matching placbo (2: 1) or to pyrimethamine or matching placebo (2: 1). The clindamycin arm of the study was terminated after a median follow-up of three months due to dose-limiting toxcities; the pyrimethamine arm was terminated after a median follow-up of eight months due to a very low TE event rate in the placebo and pyrimethamine groups and a higher death rate among patients assigned pyrimethamine.

Original languageEnglish (US)
Title of host publicationData Monitoring in Clinical Trials
Subtitle of host publicationA Case Studies Approach
PublisherSpringer US
Pages320-329
Number of pages10
ISBN (Print)0387203303, 9780387203300
DOIs
StatePublished - Dec 1 2006

Fingerprint Dive into the research topics of 'Data monitoring experience in the AIDS toxoplasmic encephalitis study'. Together they form a unique fingerprint.

Cite this